Hikma Pharmaceuticals (OTCMKTS:HKMPF) vs. Corcept Therapeutics (NASDAQ:CORT) Head-To-Head Survey

Hikma Pharmaceuticals (OTCMKTS:HKMPF) and Corcept Therapeutics (NASDAQ:CORT) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Volatility & Risk

Hikma Pharmaceuticals has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500.

Institutional & Insider Ownership

93.6% of Corcept Therapeutics shares are owned by institutional investors. 20.8% of Corcept Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Hikma Pharmaceuticals and Corcept Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hikma Pharmaceuticals	$3.13 billion	1.46	$359.00 million	N/A	N/A
Corcept Therapeutics	$741.17 million	10.97	$141.21 million	$0.88	87.83

Hikma Pharmaceuticals has higher revenue and earnings than Corcept Therapeutics.

Analyst Ratings

This is a summary of current recommendations for Hikma Pharmaceuticals and Corcept Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hikma Pharmaceuticals	0	0	1	0	3.00
Corcept Therapeutics	1	2	4	0	2.43

Corcept Therapeutics has a consensus target price of $135.25, suggesting a potential upside of 74.99%. Given Corcept Therapeutics’ higher possible upside, analysts plainly believe Corcept Therapeutics is more favorable than Hikma Pharmaceuticals.

Profitability

This table compares Hikma Pharmaceuticals and Corcept Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hikma Pharmaceuticals	N/A	N/A	N/A
Corcept Therapeutics	18.51%	20.10%	16.20%

Summary

Corcept Therapeutics beats Hikma Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.